Osteoporosis drug may boost fertility: new study tests denosumab on egg maturation

NCT ID NCT07546552

Recruiting now Knowledge-focused Sponsor: Peter Humaidan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether blocking a protein called RANKL can help eggs mature and improve fertility treatments. Researchers will use denosumab, a drug already approved for osteoporosis, in lab studies with human and mouse eggs. The goal is to understand if RANKL manipulation could lead to better IVF outcomes for women with infertility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Denosumab
What this could lead to: If successful, this research could point toward new ways to improve IVF success and treat female infertility by targeting RANKL.
What could go wrong: This is early-stage research in mice, human tissue, and a small number of women. It may not lead to a practical treatment, and denosumab's effects on fertility are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEMALE INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female infertility osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FEMALE INFERTILITY FOLLICLE DEVELOPMENT NF-ΚB LIGAND OSTEOPOROSIS RANKL

Contacts and locations

Locations

Regionshospitalet, Skive, Midt Jylland 7800
RECRUITING

Skive, Midt Jylland, 7800, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.